---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-046455"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:49:57.081737+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports positive early Phase 1 data for IMM-1-104; accelerates RP2D timeline to early 2024

## Summary
- IMM-1-104 shows >90% pERK inhibition at 160mg QD; PK Cmax >2,000 ng/mL; half-life ~2 hours.
- No dose-limiting toxicities or SAEs; only Grade 1 drug-related AEs; well tolerated across four patients.
- RP2D announcement accelerated to early 2024 from prior guidance of mid-2024.
- Preliminary cash $91.5M at March 31, 2023; expected funding into Q4 2024.
- Data from patients with pancreatic and colorectal cancer with KRAS G12D, G12V, NRAS Q61L, Q61K.

## SEC filing metadata
- accession: 0001104659-23-046455
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/0001104659-23-046455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000110465923046455/tm2312981d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-046455
- JSON: https://secwatch.observer/filing/0001104659-23-046455.json
- Plain text: https://secwatch.observer/filing/0001104659-23-046455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.